Chimeric Therapeutics Limited (CHM.AX)

0.0310 -0.0030 (-8.82%) At close: 04:10PM AEST

Chimeric Therapeutics Limited

62 Lygon Street
Level 3 Carlton South
Carlton, VIC 3053
Australia
61 3 9824 5254
https://www.chimerictherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD	Founder & Executive Chairman	250k	N/A	1956
Ms. Jennifer Chow	CEO, MD & Director	1.37M	N/A	N/A
Mr. Eliot Bourk	Chief Business Officer & Head of External Innovation	836.16k	N/A	N/A
Mr. Jason B. Litten M.D.	Chief Medical Officer	1.02M	N/A	1974
Mr. Phillip Allen Hains BBus(Acc), C.A., M.B.A.	CFO, Joint Company Secretary & Director	N/A	N/A	1959
Mr. Kelly R. Thornburg	VP & Head of Quality	N/A	N/A	1963
Mr. Nathan Jong C.A.	Company Secretary	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies in oncology in Australia. The company develops CHM 0201 (core NK platform) that is in phase I clinical trial for treating solid tumors and hematological malignancies; and CHM 1101 (CLTX CAR T), which is in phase I clinical trial for treating patients with MMP2+ recurrent or progressive glioblastoma. It is also developing CHM 0301 for blood cancers; CHM 1301 (CLTX CAR NK) and CHM 2301 (CDH17 CAR NK) for solid tumors; CHM 1101 (CLTX CAR T) for melanoma, colorectal, and prostate; and CHM 2101 (CDH17 CAR T) for neuroendocrine, colorectal, pancreatic, and gastric. The company was incorporated in 2020 and is based in Carlton, Australia.

Corporate governance

Chimeric Therapeutics Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.